Kinase Inhibitor [EPC]

554646 reported adverse events

Drugs of this class: SIROLIMUS EVEROLIMUS NILOTINIB GEFITINIB SORAFENIB BOSUTINIB PALBOCICLIB ACALABRUTINIB AXITINIB LAROTRECTINIB LORLATINIB

These side effects are most commonly reported by patients taking drugs of the Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 61808
1 FATIGUE 49612
2 DIARRHOEA 46107
3 OFF LABEL USE 39406
4 NAUSEA 31403
5 MALIGNANT NEOPLASM PROGRESSION 20956
6 ASTHENIA 19666
7 DECREASED APPETITE 18629
8 RASH 18315
9 VOMITING 17425
See all common reactions for Kinase Inhibitor [EPC]

Drugs of the Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EGFR GENE MUTATION 317 0.8499
1 ACQUIRED GENE MUTATION 678 0.5203
2 NEOPLASM PROGRESSION 16299 0.4706
3 TRYPTASE INCREASED 294 0.4236
4 CARBOHYDRATE ANTIGEN 15-3 INCREASED 253 0.3364
5 MYELOFIBROSIS 998 0.3336
6 METASTASES TO MENINGES 714 0.3229
7 HAEMATOCRIT ABNORMAL 375 0.3074
8 MANTLE CELL LYMPHOMA 454 0.3031
9 TUMOUR MARKER INCREASED 1369 0.2884
See all enriched reactions for Kinase Inhibitor [EPC]